Dr.Reddy’s launches Atomoxetine Capsules, USP in the U.S. Market
31 October 2018 | News
Dr. Reddy’s Atomoxetine Capsules, USP is available in 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100 mg with 30 counts bottle size
Dr. Reddy’s Laboratories Ltd., along with its subsidiaries together referred to as “Dr. Reddy’s” today announced the launch of Atomoxetine Capsules, USP, a therapeutic equivalent generic version of Strattera® (atomoxetine) Capsules in the United States market approved by the U.S. Food and Drug Administration (USFDA).
The Strattera® brand and generic had U.S. sales of approximately $304 million MAT for the most recent twelve months ending in August 2018 according to IMS Health.
Dr. Reddy’s Atomoxetine Capsules, USP is available in 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100 mg with 30 counts bottle size.
Straterra® is a registered trademark of Eli Lilly and Company.
